Participants with Treatment-emergent Adverse Experiences Up to Day 169 [clinicaltrials_resource:6e9c4963f7323f80f777d1f36e2470ed]
BSAP is a biomarker of bone formation.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Participants with Treatment-emergent Adverse Experiences Up to Day 169 [clinicaltrials_resource:6e9c4963f7323f80f777d1f36e2470ed]
BSAP is a biomarker of bone formation.
Bio2RDF identifier
6e9c4963f7323f80f777d1f36e2470ed
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6e9c4963f7323f80f777d1f36e2470ed
measure [clinicaltrials_vocabulary:measure]
Participants with Treatment-emergent Adverse Experiences
time frame [clinicaltrials_vocabulary:time-frame]
Up to Day 169
description
BSAP is a biomarker of bone formation.
identifier
clinicaltrials_resource:6e9c4963f7323f80f777d1f36e2470ed
title
Participants with Treatment-emergent Adverse Experiences Up to Day 169
@en
type
label
Participants with Treatment-em ...... c4963f7323f80f777d1f36e2470ed]
@en